\documentclass[11pt,twoside]{article}\makeatletter \IfFileExists{xcolor.sty}% {\RequirePackage{xcolor}}% {\RequirePackage{color}} \usepackage{colortbl} \usepackage{wrapfig} \usepackage{ifxetex} \ifxetex \usepackage{fontspec} \usepackage{xunicode} \catcode`⃥=\active \def⃥{\textbackslash} \catcode`❴=\active \def❴{\{} \catcode`❵=\active \def❵{\}} \def\textJapanese{\fontspec{Noto Sans CJK JP}} \def\textChinese{\fontspec{Noto Sans CJK SC}} \def\textKorean{\fontspec{Noto Sans CJK KR}} \setmonofont{DejaVu Sans Mono} \else \IfFileExists{utf8x.def}% {\usepackage[utf8x]{inputenc} \PrerenderUnicode{–} }% {\usepackage[utf8]{inputenc}} \usepackage[english]{babel} \usepackage[T1]{fontenc} \usepackage{float} \usepackage[]{ucs} \uc@dclc{8421}{default}{\textbackslash } \uc@dclc{10100}{default}{\{} \uc@dclc{10101}{default}{\}} \uc@dclc{8491}{default}{\AA{}} \uc@dclc{8239}{default}{\,} \uc@dclc{20154}{default}{ } \uc@dclc{10148}{default}{>} \def\textschwa{\rotatebox{-90}{e}} \def\textJapanese{} \def\textChinese{} \IfFileExists{tipa.sty}{\usepackage{tipa}}{} \fi \def\exampleFont{\ttfamily\small} \DeclareTextSymbol{\textpi}{OML}{25} \usepackage{relsize} \RequirePackage{array} \def\@testpach{\@chclass \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else \ifnum \@lastchclass=7 5 \else \ifnum \@lastchclass=8 \tw@ \else \ifnum \@lastchclass=9 \thr@@ \else \z@ \ifnum \@lastchclass = 10 \else \edef\@nextchar{\expandafter\string\@nextchar}% \@chnum \if \@nextchar c\z@ \else \if \@nextchar l\@ne \else \if \@nextchar r\tw@ \else \z@ \@chclass \if\@nextchar |\@ne \else \if \@nextchar !6 \else \if \@nextchar @7 \else \if \@nextchar (8 \else \if \@nextchar )9 \else 10 \@chnum \if \@nextchar m\thr@@\else \if \@nextchar p4 \else \if \@nextchar b5 \else \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi} \gdef\arraybackslash{\let\\=\@arraycr} \def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}} \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \def\abbr{} \def\corr{} \def\expan{} \def\gap{} \def\orig{} \def\reg{} \def\ref{} \def\sic{} \def\persName{}\def\name{} \def\placeName{} \def\orgName{} \def\textcal#1{{\fontspec{Lucida Calligraphy}#1}} \def\textgothic#1{{\fontspec{Lucida Blackletter}#1}} \def\textlarge#1{{\large #1}} \def\textoverbar#1{\ensuremath{\overline{#1}}} \def\textquoted#1{‘#1’} \def\textsmall#1{{\small #1}} \def\textsubscript#1{\@textsubscript{\selectfont#1}} \def\textxi{\ensuremath{\xi}} \def\titlem{\itshape} \newenvironment{biblfree}{}{\ifvmode\par\fi } \newenvironment{bibl}{}{} \newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par } \newenvironment{citbibl}{}{\ifvmode\par\fi } \newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi } \newenvironment{docDate}{}{\ifvmode\par\fi } \newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi } \newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par } \newenvironment{msHead}{\vskip 6pt}{\par} \newenvironment{msItem}{\vskip 6pt}{\par} \newenvironment{rubric}{}{} \newenvironment{titlePart}{}{\par } \newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}} \newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}} \newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}} \newcolumntype{P}[1]{){\arraybackslash}p{#1}} \newcolumntype{B}[1]{){\arraybackslash}b{#1}} \newcolumntype{M}[1]{){\arraybackslash}m{#1}} \definecolor{label}{gray}{0.75} \def\unusedattribute#1{\sout{\textcolor{label}{#1}}} \DeclareRobustCommand*{\xref}{\hyper@normalise\xref@} \def\xref@#1#2{\hyper@linkurl{#2}{#1}} \begingroup \catcode`\_=\active \gdef_#1{\ensuremath{\sb{\mathrm{#1}}}} \endgroup \mathcode`\_=\string"8000 \catcode`\_=12\relax \usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry} \usepackage{framed} \definecolor{shadecolor}{gray}{0.95} \usepackage{longtable} \usepackage[normalem]{ulem} \usepackage{fancyvrb} \usepackage{fancyhdr} \usepackage{graphicx} \usepackage{marginnote} \renewcommand{\@cite}[1]{#1} \renewcommand*{\marginfont}{\itshape\footnotesize} \def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif} \pagestyle{fancy} \usepackage[pdftitle={Prevalence, Risk Factors and Awareness about HCV Infection in Pregnant Women in a Tertiary Care Center in North India}, pdfauthor={}]{hyperref} \hyperbaseurl{} \paperwidth210mm \paperheight297mm \def\@pnumwidth{1.55em} \def\@tocrmarg {2.55em} \def\@dotsep{4.5} \setcounter{tocdepth}{3} \clubpenalty=8000 \emergencystretch 3em \hbadness=4000 \hyphenpenalty=400 \pretolerance=750 \tolerance=2000 \vbadness=4000 \widowpenalty=10000 \renewcommand\section{\@startsection {section}{1}{\z@}% {-1.75ex \@plus -0.5ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large\bfseries}} \renewcommand\subsection{\@startsection{subsection}{2}{\z@}% {-1.75ex\@plus -0.5ex \@minus- .2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large}} \renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}% {-1.5ex\@plus -0.35ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\large}} \renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}% {-1ex \@plus-0.35ex \@minus -0.2ex}% {0.5ex \@plus .2ex}% {\reset@font\normalsize}} \renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}% {1.5ex \@plus1ex \@minus .2ex}% {-1em}% {\reset@font\normalsize\bfseries}} \def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt} \@tempdima 1.5em \begingroup \parindent \z@ \rightskip \@pnumwidth \parfillskip -\@pnumwidth \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par \endgroup} \def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}} \def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}} \def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}} \def\l@subparagraph{\@dottedtocline{5}{10em}{5em}} \@ifundefined{c@section}{\newcounter{section}}{} \@ifundefined{c@chapter}{\newcounter{chapter}}{} \newif\if@mainmatter \@mainmattertrue \def\chaptername{Chapter} \def\frontmatter{% \pagenumbering{roman} \def\thechapter{\@roman\c@chapter} \def\theHchapter{\roman{chapter}} \def\thesection{\@roman\c@section} \def\theHsection{\roman{section}} \def\@chapapp{}% } \def\mainmatter{% \cleardoublepage \def\thechapter{\@arabic\c@chapter} \setcounter{chapter}{0} \setcounter{section}{0} \pagenumbering{arabic} \setcounter{secnumdepth}{6} \def\@chapapp{\chaptername}% \def\theHchapter{\arabic{chapter}} \def\thesection{\@arabic\c@section} \def\theHsection{\arabic{section}} } \def\backmatter{% \cleardoublepage \setcounter{chapter}{0} \setcounter{section}{0} \setcounter{secnumdepth}{2} \def\@chapapp{\appendixname}% \def\thechapter{\@Alph\c@chapter} \def\theHchapter{\Alph{chapter}} \appendix } \newenvironment{bibitemlist}[1]{% \list{\@biblabel{\@arabic\c@enumiv}}% {\settowidth\labelwidth{\@biblabel{#1}}% \leftmargin\labelwidth \advance\leftmargin\labelsep \@openbib@code \usecounter{enumiv}% \let\p@enumiv\@empty \renewcommand\theenumiv{\@arabic\c@enumiv}% }% \sloppy \clubpenalty4000 \@clubpenalty \clubpenalty \widowpenalty4000% \sfcode`\.\@m}% {\def\@noitemerr {\@latex@warning{Empty `bibitemlist' environment}}% \endlist} \def\tableofcontents{\section*{\contentsname}\@starttoc{toc}} \parskip0pt \parindent1em \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \newenvironment{reflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemsep}{0pt}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\itshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{sansreflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\itemsep}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\upshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{specHead}[2]% {\vspace{20pt}\hrule\vspace{10pt}% \phantomsection\label{#1}\markright{#2}% \pdfbookmark[2]{#2}{#1}% \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}% }{} \def\TheFullDate{2020-01-15 (revised: 15 January 2020)} \def\TheID{\makeatother } \def\TheDate{2020-01-15} \title{Prevalence, Risk Factors and Awareness about HCV Infection in Pregnant Women in a Tertiary Care Center in North India} \author{}\makeatletter \makeatletter \newcommand*{\cleartoleftpage}{% \clearpage \if@twoside \ifodd\c@page \hbox{}\newpage \if@twocolumn \hbox{}\newpage \fi \fi \fi } \makeatother \makeatletter \thispagestyle{empty} \markright{\@title}\markboth{\@title}{\@author} \renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@ \belowdisplayskip \abovedisplayskip \abovedisplayshortskip \z@ plus2\p@ \belowdisplayshortskip 4\p@ plus2\p@ minus2\p@ \def\@listi{\leftmargin\leftmargini \topsep 2\p@ plus1\p@ minus1\p@ \parsep 2\p@ plus\p@ minus\p@ \itemsep 1pt} } \makeatother \fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm} \fancyhf{} \setlength{\headheight}{14pt} \fancyhead[LE]{\bfseries\leftmark} \fancyhead[RO]{\bfseries\rightmark} \fancyfoot[RO]{} \fancyfoot[CO]{\thepage} \fancyfoot[LO]{\TheID} \fancyfoot[LE]{} \fancyfoot[CE]{\thepage} \fancyfoot[RE]{\TheID} \hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true} \fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}} \date{} \usepackage{authblk} \providecommand{\keywords}[1] { \footnotesize \textbf{\textit{Index terms---}} #1 } \usepackage{graphicx,xcolor} \definecolor{GJBlue}{HTML}{273B81} \definecolor{GJLightBlue}{HTML}{0A9DD9} \definecolor{GJMediumGrey}{HTML}{6D6E70} \definecolor{GJLightGrey}{HTML}{929497} \renewenvironment{abstract}{% \setlength{\parindent}{0pt}\raggedright \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt \textcolor{GJBlue}{\large\bfseries\abstractname\space} }{% \vskip8pt \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt } \usepackage[absolute,overlay]{textpos} \makeatother \usepackage{lineno} \linenumbers \begin{document} \author[1]{Dr. Renu Gupta} \author[2]{Dr. Rashmi Kumari} \author[3]{Dr. Shaily Agarwal} \author[4]{Dr. Kiran Pandey} \author[5]{Dr. Neena Gupta} \author[6]{Dr. Pavika Lal} \renewcommand\Authands{ and } \date{\small \em Received: 10 December 2019 Accepted: 31 December 2019 Published: 15 January 2020} \maketitle \begin{abstract} Among the viral infections affecting the liver in pregnancy, Hepatitis C though uncommon now is recognized to be a serious global public health problem affecting 170 million people worldwide I .e. 3% of the population [1]. The prevalence of anti-HCV antibody in pregnant women in developed countries ranges from 0.14 to 4.4 %, whereas the seroprevalence in Indian pregnant female population is 1.03 % [2,3, 4]. Following the decreasing transmission of HCV by blood -transfusion, intravenous drug use has now become the primary route of new HCV infections in adults while mother to child transmission (MTCT) is the major route of new infections in young children in the developed as well as in developing countries.[5] Approximately 7â??"8 % of hepatitis C virus-positive women transmit this virus to their offspring [6] mainly because they are ignorant about this infection and unaware of their status. The natural course of hepatitis C is a progression from acute hepatitis to chronic hepatitis, which occurs in 55%-85 % of patients. \end{abstract} \keywords{} \begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) \textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark} \end{textblock*} \begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) \textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}} \end{textblock*} \let\tabcellsep& \par Introduction-Among the viral infections affecting the liver in pregnancy, Hepatitis C though uncommon now is recognized to be a serious global public health problem affecting 170 million people worldwide I .e. 3\% of the population \hyperref[b0]{[1]}. The prevalence of anti-HCV antibody in pregnant women in developed countries ranges from 0.14 to 4.4 \%, whereas the seroprevalence in Indian pregnant female population is 1.03 \% \hyperref[b1]{[2,}\hyperref[b2]{3,}\hyperref[b3]{4]}. Following the decreasing transmission of HCV by blood -transfusion, intravenous drug use has now become the primary route of new HCV infections in adults while mother to child transmission (MTCT) is the major route of new infections in young children in the developed as well as in developing countries. \hyperref[b4]{[5]} Approximately 7-8 \% of hepatitis C virus-positive women transmit this virus to their offspring \hyperref[b5]{[6]} mainly because they are ignorant about this infection and unaware of their status. The natural course of hepatitis C is a progression from acute hepatitis to chronic hepatitis, which occurs in 55\%-85 \% of patients. \section[{Introduction}]{Introduction}\par mong the viral infections affecting the liver in pregnancy, Hepatitis C though uncommon now is recognized to be a serious global public health problem affecting 170 million people worldwide I .e. 3\% of the population \hyperref[b0]{[1]}. The prevalence of anti-HCV antibody in pregnant women in developed countries ranges from 0.14 to 4.4 \%, whereas the seroprevalence in Indian pregnant female population is 1.03 \% \hyperref[b1]{[2,}\hyperref[b2]{3,}\hyperref[b3]{4]}.\par Following the decreasing transmission of HCV by blood -transfusion, intravenous drug use has now become the primary route of new HCV infections in adults while mother to child transmission (MTCT) is the major route of new infections in young children in the developed as well as in developing countries. \hyperref[b4]{[5]} Approximately 7-8 \% of hepatitis C virus-positive women transmit this virus to their offspring \hyperref[b5]{[6]} mainly because they are ignorant about this infection and unaware of their status. The natural course of hepatitis C is a progression from acute hepatitis to chronic hepatitis, which occurs in 55\%-85 \% of patients.\par Hepatitis C infection leads to chronic liver disease, cirrhosis as well as known to cause hepatocellular carcinoma. Still World Health Organization (WHO) do not recommend the universal screening of Hepatitis B and C in pregnant women, although testing of HIV is mandatory after proper voluntary counseling. The study was undertaken with the aim to assess the exclusive seroprevalence of Hepatitis C infection in pregnant females and to know the risk factors, their attitude, and awareness against this dreadful disease. \section[{II.}]{II.} \section[{Material and Methods}]{Material and Methods}\par This was a prospective observational study done at our tertiary care center in the obstetrics and gynecology department of UISEMH,GSVM Medical College in Kanpur(India) from November 2017 to August 2019.After taking a proper written informed consent, all antenatal women attending the OPD and in emergency who were exclusively HCV positive were included in the study group. Age, Parity, Gestational age-matched women delivering during the same time frame who were tested negative for HCV were taken as controls. The initially reactive samples were re-tested and considered ELISA positive if both results were reactive. Once hepatitis C was diagnosed, a qualitative HCV RNA test was done to determine the baseline viral load by RNA PCR. A structured questionnaire was prepared comprising of questions and a face to face interview was done to know the awareness of viral infections during the antenatal period.\par Those previously diagnosed to have some chronic liver disease, Intrahepatic cholestasis of pregnancy, or co-infection with HIV and Hepatitis B were excluded from the study. Laboratory tests to evaluate the extent of liver disease were done, including the following: Bilirubin, ALT, AST, albumin, platelet count, and prothrombin time. A total of 5853 antenatal patients had reported during the study period, out of which 126 were found to be HCV positive. The patients were further advised for HCV RNA, but only 98 had opted for HCV RNA.\par Statistical Analysis-Data was analyzed using SPSS 22.0.Categorical variables were analyzed using the Odds ratio (OD), and the Chi-square test \& p-value <0.05 were considered significant. The study has been approved by the Ethics Committee of GSVM Medical College, Kanpur. \section[{III.}]{III.} \section[{Results}]{Results}\par One hundred twenty-six (2.15 \%) of the 5853 pregnant women tested positive for anti HCV antibodies. Of these, 72 (73.4\%) were positive for HCV RNA by RT -PCR. Most of the HCV reactive obstetric patients were in the reproductive age group and the mean age was 26. years. Slightly higher rate of infection was found among women living in rural areas, which was 58.7\% while that in the urban area was 41.2\%.Both study and control groups had similar educational qualifications. (Table \hyperref[tab_0]{1})\par Most patients in the study group belonged to lower socioeconomic status. In the HCV infected group, 44.4 \% patients belonged to lower socioeconomic status, while only 26.9\% were of upper socioeconomic status. 46.8\% were diagnosed in the intrapartum period, while only 38\% were diagnosed during their antenatal visits among the risk factors for HCV infection previous history of blood transfusions, dilatation and curettage, previous surgery were studied as independent risk factors (Table \hyperref[tab_1]{2}). The majority, 52.7\% of the RNA positive patients and 46.1 \% in RNA negative had a history of any surgery (Table \hyperref[tab_2]{3}). Of the 126 HCV positive patients, 22\% did not have any identifiable risk factors. Of the 5853 patients questioned, maximum awareness was about HIV and least about HCV (Table \hyperref[tab_3]{4}). \section[{Discussion}]{Discussion}\par Our study represents a single hospital-based report to define the seroprevalence, risk factors, and knowledge of hepatitis C infection in our patient population of pregnant women which usually caters to Kanpur and it's adjoining areas (Kanpur-Dehat).\par The study also found a higher rate of infection among women living in rural areas, with higher parity and those belonging to rural areas. Higher infection rates among rural residents may be partially explained by the higher prevalence of anemia among rural women. Leiken et al. have reported a higher mean parity of HCV positive patients in their study \hyperref[b9]{[10]}. They might be at increased risk because of their past pregnancies, hospital admissions, past surgeries, obstetrical procedures, and blood transfusions. It was found that 73.4\% of the anti-HCV antibody-positive pregnant women had detectable HCV RNA in their blood, a figure that is similar to that found in most of the studies. \hyperref[b14]{[15]}\hyperref[b15]{[16]}\hyperref[b16]{[17]} We found no significant association with maternal and neonatal morbidity, but there are few studies which reveal increased risk of obstetric complications, but they had a few sample size, which \section[{HIV}]{HIV}\par The prevalence of Hepatitis C positive pregnant women was found to be 2.15 \% in our study, which is almost double the reported prevalence of 1.03\% in a study from North India by Kumar A et al. \hyperref[b6]{[7]} and similar to the findings of other epidemiologic studies \hyperref[b2]{[3,}\hyperref[b10]{11]}. Prevalence in western countries ranges from 0.14 to 4.4\% due to more awareness towards one's health, education and better health care facilities \hyperref[b1]{[2,}\hyperref[b2]{3]}. The highest prevalence of infection occurs among the individuals of the reproductive age group 25-35 years because this is the peak age group and also at the same time explains the increased chances of exposure of these group of women to risk factors. \hyperref[b7]{[8,}\hyperref[b8]{9,}\hyperref[b9]{10]}.\par Earlier studies by {\ref Bohman VR et al.} have found an association between the prevalence of HCV and the known risk factors of this infection \hyperref[b10]{[11]}. In our study, history of D \& C, surgery, and blood transfusion were found to be major risk factors for transmission of HCV infection. Patients are exposed to unsterilized instrumentation where D\&C is done by paramedical staff without maintaining aseptic conditions .Also in a study by {\ref Hutin Y et al.}, it has been reported that in resourcepoor countries, the risk of iatrogenic HCV infection is high \hyperref[b11]{[12]}. Intravenous drug abuse is a significant risk factor in western countries \hyperref[b12]{[13]}. In a study from Northern Italy, the principal risk factors were a history of intravenous drug abuse (32\%) and exposure to blood products (24\%).\par was inconclusive. In our study there was no significant variation in the level of liver enzymes Serum transaminases and total bilirubin. This finding was similar to a study by Paternoster et al. \hyperref[b13]{[14]} supporting the immune-mediated hypothesis.\par In the present study, it was found that a substantial proportion of women with HCV had no evidence of exposure to any known risk factors in their history, about 22\% of patients did not have any identifiable risk factor. This is comparable with the observation by Ward C et al. \hyperref[b14]{[15]}, that 40-73\% of the women had no obvious risk factors for HCV infection at the time of booking. It has been found that selective antenatal screening policy based on risk factors, failed to identify over half of infected patients. \hyperref[b17]{[18]} Routine antenatal HCV screening is not mandatory in India, but identification of HCV in pregnant women is important because of their risk of long term complications of infection, potential effects on pregnancy, and risk of transmission to their infants. Therefore universal screening for HCV can be recommended.\par V. \section[{Conclusion}]{Conclusion}\par In our study, we found that there is high prevalence of Hepatitis C infection pregnant women posing a public health problem. Organizational bodies such as American College of Obstetricians and Gynecologists and Society for Maternal and Fetal medicine recommend selective antenatal screening solely based on high-risk factors which fail to identify over half of the infected patients, therefore universal screening in a pregnant female is justifiable and should be recommended to identify patients without any risk factors. Although it does not adversely affect the maternal or the neonatal outcome, but hepatitis C has long term ill effects on the health of both the mother and the child.\par The need of the hour is to increase the awareness of hepatitis C infection by implementing educational programs through mass media as presently done for HIV infection as well as by emphasis on preventive measures such as sterilization of instruments, screening blood and blood products and making services more accessible with increasing utilization of antenatal services in rural areas. \begin{figure}[htbp] \noindent\textbf{1} \par \begin{longtable}{P{0.44330143540669853\textwidth}P{0.19521531100478468\textwidth}P{0.21148325358851675\textwidth}} \tabcellsep \multicolumn{2}{l}{HCV POSITIVE(N=126)}\\ \tabcellsep NUMBER\tabcellsep PERCENTAGE\\ TOTAL\tabcellsep 126\tabcellsep \%\\ AGE\tabcellsep \tabcellsep \\ 15-24 year\tabcellsep 41\tabcellsep 32.5\\ 25-35\tabcellsep 80\tabcellsep 63.5\\ >35\tabcellsep 05\tabcellsep 3.9\\ HABITAT\tabcellsep \tabcellsep \\ Rural\tabcellsep 74\tabcellsep 58.7\\ Urban\tabcellsep 52\tabcellsep 41.2\\ PARITY\tabcellsep \tabcellsep \\ Nullipara\tabcellsep 27\tabcellsep 21.4\\ Multipara\tabcellsep 99\tabcellsep 78.5\\ EDUCATION STATUS\tabcellsep \tabcellsep \\ Illiterate\tabcellsep 51\tabcellsep 40.4\\ Primary\tabcellsep 58\tabcellsep 46.0\\ Secondary\tabcellsep 17\tabcellsep 13.49\end{longtable} \par \caption{\label{tab_0}Table 1 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{2} \par \begin{longtable}{P{0.24491525423728813\textwidth}P{0.1930508474576271\textwidth}P{0.043220338983050846\textwidth}P{0.10084745762711865\textwidth}P{0.16135593220338984\textwidth}P{0.10661016949152541\textwidth}} \tabcellsep \multicolumn{3}{l}{HCV Positive}\tabcellsep \\ Risk Factors\tabcellsep \multicolumn{2}{l}{(n=126) HCV RNA Positive}\tabcellsep HCV RNA\tabcellsep HCV Negative (n =5727)\tabcellsep p-value\\ \tabcellsep (n =72)\tabcellsep \multicolumn{2}{l}{negative (n=26)}\tabcellsep \\ H/O Blood transfusion\tabcellsep 16\tabcellsep \tabcellsep 9\tabcellsep 456\tabcellsep <0.001*\\ \tabcellsep 32\%\tabcellsep \tabcellsep 40.9\%\tabcellsep 8.0\%\\ H/O Abortions\tabcellsep 04\tabcellsep \tabcellsep 03\tabcellsep 1125\tabcellsep <0.001*\\ \tabcellsep 8\%\tabcellsep \tabcellsep 13.6\%\tabcellsep 19.6\%\\ H/O multiple sex partners\tabcellsep 03\tabcellsep \tabcellsep 02\tabcellsep 25\tabcellsep 0.00001*\\ \tabcellsep 4.1\%\tabcellsep \tabcellsep 7.6\%\tabcellsep 0.43\%\\ H/O Episiotomy\tabcellsep 24\tabcellsep \tabcellsep 12\tabcellsep 3818\tabcellsep 0.00001*\\ \tabcellsep 33.3\tabcellsep \tabcellsep 46.1\tabcellsep 66.6\end{longtable} \par \caption{\label{tab_1}Table 2 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{3} \par \begin{longtable}{P{0.234375\textwidth}P{0.19374999999999998\textwidth}P{0.15312499999999998\textwidth}P{0.175\textwidth}P{0.09375\textwidth}} \tabcellsep \multicolumn{2}{l}{HCV Positive}\tabcellsep \tabcellsep p\\ Risk factors\tabcellsep HCV RNA positive\tabcellsep HCV RNA negative\tabcellsep HCV Negative (n= 5727)\tabcellsep value\\ \tabcellsep (n=72)\tabcellsep (n=26)\tabcellsep \tabcellsep \\ H/O D\&C\tabcellsep 06\tabcellsep 04\tabcellsep 987\tabcellsep 0.00603*\\ \tabcellsep 12\%\tabcellsep 18.2\%\tabcellsep 17.2\%\tabcellsep \\ H/O Previous\tabcellsep 15\tabcellsep 7\tabcellsep 1007\tabcellsep 0.041*\\ surgery\tabcellsep 30\%\tabcellsep 31.8\%\tabcellsep 17.6\%\tabcellsep \\ H/O Dental\tabcellsep 01\tabcellsep 00\tabcellsep 12\tabcellsep 0.168\\ procedure\tabcellsep 1.38\%\tabcellsep 00\tabcellsep 0.2\%\tabcellsep \\ H/O Amniocentesis\tabcellsep 01\tabcellsep 00\tabcellsep 24\tabcellsep 0.523\\ \tabcellsep 0.79\%\tabcellsep 1.38\%\tabcellsep 0.41\%\tabcellsep \end{longtable} \par \caption{\label{tab_2}Table 3 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{4} \par \begin{longtable}{} \end{longtable} \par \caption{\label{tab_3}Table 4 :}\end{figure} \backmatter \begin{bibitemlist}{1} \bibitem[Wasley et al. ()]{b8}\label{b8} \textit{}, A D Wasley , Epidemeology Altermj , C Of Hepatitis . \textit{Semin Liver Dis} 2000. 20 p. . \bibitem[American college of obstetricians and gynecologists ACOG Educational Bulletin Viral hepatitis in pregnancy. Number (1998)]{b5}\label{b5} ‘American college of obstetricians and gynecologists’. \textit{ACOG Educational Bulletin Viral hepatitis in pregnancy. Number} July 1998. 1998. 248 p. . (Int J Gynaecol Obstet) \bibitem[Centres for disease control and prevention, Recommendations for prevention and control of Hepatitis C virus (HCV) infection and HCV related disease Morb Mortal Wkly Rep ()]{b7}\label{b7} ‘Centres for disease control and prevention, Recommendations for prevention and control of Hepatitis C virus (HCV) infection and HCV related disease’. \textit{Morb Mortal Wkly Rep} 1998. 47 p. . \bibitem[Saez et al. ()]{b15}\label{b15} ‘Diagnostic and prognostic value of virologic tests in vertical transmission of hepatitis C virus infection: results of a large prospective study in pregnant women’. A Saez , Losam , Loiaconoo , Lozanoc , Alvareze , Pital . \textit{Hepatogastroenterology} 2004. 51 p. . \bibitem[Leikin et al. ()]{b9}\label{b9} ‘Epidemeological predictors of hepatitis C virus infection in pregnant women’. E L Leikin , J F Reinus , Schmell , N Tejani . \textit{ObstetGynecol} 1994. 84 p. . \bibitem[Baldo et al. ()]{b0}\label{b0} ‘Epidemiology of HCV infection’. V Baldo , T Baldovin , R Trivello . \xref{http://dx.doi.org/10.2174/138161208784746770}{10.2174/138161208784746770}. \textit{Curr Pharm Des} 2008. 14 p. . \bibitem[Silverman et al. ()]{b2}\label{b2} ‘Hepatitis C virus in pregnancy: seroprevalence and risk factors for infection’. N S Silverman , B K Jenkin , C Wu . \xref{http://dx.doi.org/10.1016/0002-9378(93)90627-U}{10.1016/0002-9378(93)90627-U}. \textit{Am J Obstet Gynecol} 1993. 169 p. . \bibitem[Arshad et al. ()]{b4}\label{b4} ‘Hepatitis C virus infection during pregnancy and the newborn period are they opportunities for treatment’. M Arshad , S S El-Kamary , R Jhaveri . \textit{Journal of viral hepatitis} 2011. 18 p. . \bibitem[Jabeen et al. ()]{b17}\label{b17} ‘Pregnancy and pregnancy outcome in hepatitis C type 1b’. T Jabeen , Cannonb , J Hogan . \textit{QJM} 2000. 93 p. . \bibitem[Pergam et al. ()]{b12}\label{b12} ‘Pregnancy complications associated with hepatitis C: data from a 2003-2005 Washington state birth cohort’. S A Pergam , C C Wang , C M Gardella . 38.el- 38.e9. \textit{Am J Obstet Gynecol} 2008. 199 (1) . \bibitem[Kumar et al. ()]{b3}\label{b3} ‘Prevalence \& risk factors for hepatitis C virus among pregnant women’. A Kumar , K A Sharma , R K Gupta . \textit{Indian J Med Res} 2007. 126 p. . \bibitem[Kumar et al. ()]{b6}\label{b6} ‘Prevalence \& risk factors for hepatitis C virus among pregnant women’. A Kumar , K A Sharma , R K Gupta . \textit{Indian J Med Res} 2007. 126 p. . \bibitem[Conte et al. ()]{b16}\label{b16} ‘Prevalence and clinical course of chronic hepatitis C virus infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women’. D Conte , Fraquellim , D Prati , A Colucci , E Minola . \textit{Hepatology} 2000. 31 p. . \bibitem[Ward et al. ()]{b1}\label{b1} ‘Prevalence of hepatitis C among pregnant women attending an inner London obstetric department: uptake and acceptability of named antenatal testing’. C Ward , G Tudor-Williams , T Cotzias . \xref{http://dx.doi.org/10.1136/gut.47.2.277}{10.1136/gut.47.2.277}. \textit{Gut} 2000. 47 (2) p. . \bibitem[Ward et al. ()]{b14}\label{b14} ‘Prevalence of hepatitis C among pregnant women attending an inner London obstetric department: uptake and acceptability of named antenatal testing’. C Ward , Tudor Williams , G Cotziast , S Hargreaves , L Regan , Fostergr . \textit{Gut} 2000. 47 p. . \bibitem[Bohman et al. ()]{b10}\label{b10} ‘Seroprevalence and risk factors for hepatitis C Virus in pregnant women’. V R Bohman , Stettlerw , Littlebb , Wendelgd , Sutorlj , F G Cunningham . \textit{ObstetGynecol} 1992. 80 p. . \bibitem[Hutin and Hauria ()]{b11}\label{b11} ‘Use of injections in healthcare settings worldwide, 000: literature review and regional estimates’. Y Hutin , Armstrongg Hauria . \textit{BMJ} 2003. 327 p. . \bibitem[Peternoster et al. ()]{b13}\label{b13} ‘Viral load in HCV RNA-positive pregnant women’. D M Peternoster , C Santarossa , P Grella . \textit{Am J Gastroentrol} 2001. 96 (9) p. . \end{bibitemlist} \end{document}